302 related articles for article (PubMed ID: 16740036)
1. High proliferative activity excludes dermatofibroma: report of the utility of MIB-1 in the differential diagnosis of selected fibrohistiocytic tumors.
Hanly AJ; Jordà M; Elgart GW; Badiavas E; Nassiri M; Nadji M
Arch Pathol Lab Med; 2006 Jun; 130(6):831-4. PubMed ID: 16740036
[TBL] [Abstract][Full Text] [Related]
2. Low proliferative activity in common dermatofibroma does not necessarily guarantee a low proliferation in all dermatofibroma variants.
Fernandez-Flores A
Arch Pathol Lab Med; 2008 Feb; 132(2):160; author reply 160-1. PubMed ID: 18251566
[No Abstract] [Full Text] [Related]
3. [Fibrohistiocytic skin tumors].
Hügel H
J Dtsch Dermatol Ges; 2006 Jul; 4(7):544-55. PubMed ID: 16827912
[TBL] [Abstract][Full Text] [Related]
4. [Fibrohistiocytic tumors of the skin: a heterogeneous group of superficially located mesenchymal neoplasms].
Mentzel T
Pathologe; 2015 Feb; 36(1):79-88. PubMed ID: 25589356
[TBL] [Abstract][Full Text] [Related]
5. Tenascin expression in cutaneous fibrohistiocytic tumors. Immunohistochemical investigation of 24 cases.
Franchi A; Santucci M
Am J Dermatopathol; 1996 Oct; 18(5):454-9. PubMed ID: 8902090
[TBL] [Abstract][Full Text] [Related]
6. LN-2 (CD74). A marker to distinguish atypical fibroxanthoma from malignant fibrous histiocytoma.
Lazova R; Moynes R; May D; Scott G
Cancer; 1997 Jun; 79(11):2115-24. PubMed ID: 9179057
[TBL] [Abstract][Full Text] [Related]
7. Fibrohistiocytic Tumors.
Romano RC; Fritchie KJ
Clin Lab Med; 2017 Sep; 37(3):603-631. PubMed ID: 28802503
[TBL] [Abstract][Full Text] [Related]
8. Apolipoprotein D in CD34-positive and CD34-negative cutaneous neoplasms: a useful marker in differentiating superficial acral fibromyxoma from dermatofibrosarcoma protuberans.
Lisovsky M; Hoang MP; Dresser KA; Kapur P; Bhawan J; Mahalingam M
Mod Pathol; 2008 Jan; 21(1):31-8. PubMed ID: 17885669
[TBL] [Abstract][Full Text] [Related]
9. Differential expression of HMGA1 and HMGA2 in dermatofibroma and dermatofibrosarcoma protuberans: potential diagnostic applications, and comparison with histologic findings, CD34, and factor XIIIa immunoreactivity.
Li N; McNiff J; Hui P; Manfioletti G; Tallini G
Am J Dermatopathol; 2004 Aug; 26(4):267-72. PubMed ID: 15249855
[TBL] [Abstract][Full Text] [Related]
10. Subcutaneous atypical fibrous histiocytoma.
Garrido-Ruiz MC; Ramos P; Enguita AB; Rodriguez Peralto JL
Am J Dermatopathol; 2009 Jul; 31(5):499-501. PubMed ID: 19542931
[TBL] [Abstract][Full Text] [Related]
11. Indeterminate fibrohistiocytic lesions of the skin: is there a spectrum between dermatofibroma and dermatofibrosarcoma protuberans?
Horenstein MG; Prieto VG; Nuckols JD; Burchette JL; Shea CR
Am J Surg Pathol; 2000 Jul; 24(7):996-1003. PubMed ID: 10895822
[TBL] [Abstract][Full Text] [Related]
12. Expression of CD163 in dermatofibroma, cellular fibrous histiocytoma, and dermatofibrosarcoma protuberans: comparison with CD68, CD34, and Factor XIIIa.
Sachdev R; Sundram U
J Cutan Pathol; 2006 May; 33(5):353-60. PubMed ID: 16640542
[TBL] [Abstract][Full Text] [Related]
13. [The ultrastructure of fibrous and histiocytic skin tumors (dermatofibroma, dermatofibrosarcoma protuberans, fibroxanthoma, and histiocytoma) (author's transl)].
Auböck L
Virchows Arch A Pathol Anat Histol; 1975 Oct; 368(3):253-74. PubMed ID: 171831
[TBL] [Abstract][Full Text] [Related]
14. Cutaneous soft tissue tumors: how do we make sense of fibrous and "fibrohistiocytic" tumors with confusing names and similar appearances?
Hornick JL
Mod Pathol; 2020 Jan; 33(Suppl 1):56-65. PubMed ID: 31653978
[TBL] [Abstract][Full Text] [Related]
15. D2-40, a novel immunohistochemical marker in differentiating dermatofibroma from dermatofibrosarcoma protuberans.
Bandarchi B; Ma L; Marginean C; Hafezi S; Zubovits J; Rasty G
Mod Pathol; 2010 Mar; 23(3):434-8. PubMed ID: 20062007
[TBL] [Abstract][Full Text] [Related]
16. Atrophic variants of dermatofibroma and dermatofibrosarcoma protuberans.
Zelger BW; Ofner D; Zelger BG
Histopathology; 1995 Jun; 26(6):519-27. PubMed ID: 7545142
[TBL] [Abstract][Full Text] [Related]
17. CD34 and factor-XIIIa immunoreactivity in dermatofibrosarcoma protuberans and dermatofibroma.
Goldblum JR; Tuthill RJ
Am J Dermatopathol; 1997 Apr; 19(2):147-53. PubMed ID: 9129699
[TBL] [Abstract][Full Text] [Related]
18. [Fibrohistiocytic tumor of skin].
Wang J
Zhonghua Bing Li Xue Za Zhi; 2013 Feb; 42(2):134-7. PubMed ID: 23710926
[No Abstract] [Full Text] [Related]
19. Deep penetrating dermatofibroma.
Laughlin CL; Carrington PR
Dermatol Surg; 1998 May; 24(5):592-4. PubMed ID: 9598017
[TBL] [Abstract][Full Text] [Related]
20. S100A6 expression in fibrohistiocytic lesions.
Fullen DR; Reed JA; Finnerty B; McNutt NS
J Cutan Pathol; 2001 May; 28(5):229-34. PubMed ID: 11401666
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]